Research Analysts Offer Predictions for Zura Bio Q3 Earnings

Zura Bio Limited (NASDAQ:ZURA) – Research analysts at HC Wainwright raised their Q3 2025 EPS estimates for shares of Zura Bio in a note issued to investors on Monday, November 11th. HC Wainwright analyst M. Kapoor now anticipates that the company will post earnings per share of ($0.23) for the quarter, up from their prior forecast of ($0.24). HC Wainwright currently has a “Neutral” rating and a $5.00 price objective on the stock. The consensus estimate for Zura Bio’s current full-year earnings is ($0.61) per share.

Other equities research analysts have also issued research reports about the stock. Leerink Partners assumed coverage on shares of Zura Bio in a research note on Monday, November 4th. They issued an “outperform” rating and a $15.00 price objective for the company. Piper Sandler reaffirmed an “overweight” rating and issued a $26.00 price objective on shares of Zura Bio in a research note on Thursday, September 19th. Leerink Partnrs raised shares of Zura Bio to a “strong-buy” rating in a research note on Monday, November 4th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Zura Bio in a report on Friday, October 18th. Finally, Chardan Capital dropped their target price on shares of Zura Bio from $14.00 to $12.00 and set a “buy” rating on the stock in a report on Friday, November 8th. One investment analyst has rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $15.80.

Zura Bio Stock Down 3.3 %

ZURA stock opened at $4.38 on Wednesday. Zura Bio has a 1 year low of $2.00 and a 1 year high of $6.35. The company has a fifty day simple moving average of $4.21 and a 200 day simple moving average of $4.13.

Zura Bio (NASDAQ:ZURA) last issued its earnings results on Thursday, November 7th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.12).

Insider Transactions at Zura Bio

In other news, Director Someit Sidhu sold 51,728 shares of the business’s stock in a transaction dated Wednesday, September 4th. The shares were sold at an average price of $3.87, for a total transaction of $200,187.36. Following the transaction, the director now owns 2,085,418 shares in the company, valued at approximately $8,070,567.66. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 22.10% of the company’s stock.

Institutional Trading of Zura Bio

Several institutional investors have recently made changes to their positions in the business. Renaissance Technologies LLC boosted its position in shares of Zura Bio by 51.3% during the 2nd quarter. Renaissance Technologies LLC now owns 17,400 shares of the company’s stock valued at $61,000 after acquiring an additional 5,900 shares in the last quarter. Bank of New York Mellon Corp boosted its position in shares of Zura Bio by 15.8% during the 2nd quarter. Bank of New York Mellon Corp now owns 47,109 shares of the company’s stock valued at $165,000 after acquiring an additional 6,412 shares in the last quarter. Forefront Analytics LLC boosted its position in shares of Zura Bio by 22.1% during the 2nd quarter. Forefront Analytics LLC now owns 41,569 shares of the company’s stock valued at $145,000 after acquiring an additional 7,531 shares in the last quarter. AQR Capital Management LLC acquired a new stake in shares of Zura Bio during the 2nd quarter valued at about $43,000. Finally, SG Americas Securities LLC acquired a new stake in shares of Zura Bio during the 3rd quarter valued at about $62,000. 61.14% of the stock is currently owned by institutional investors and hedge funds.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.